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metabolism and organelle structures, which represent in 
fact a relatively small number of cellular processes that 
could help to find common curative approaches, which are 
still lacking.
Introduction
Hereditary spastic paraplegia (HSP) refers to a group of 
neurological diseases caused by corticospinal tract degen-
eration (Tallaksen et al. 2001; Fink 2003, 2013). Approxi-
mately, 1 to 10/100,000 people are affected by HSP, 
depending on the geographical area (Ruano et al. 2014). 
Patients suffer from the presence of pyramidal signs pre-
dominating in lower limbs (LL), which include spasticity 
(stiff legs) and exaggerated reflexes, associated to muscular 
weakness that can progress to spastic paralysis of the legs 
(paraplegia) (Harding 1983; Fink 2003). Pyramidal signs in 
the upper limbs (UL), as well as distal LL muscle wasting, 
may appear after long disease durations. Spasticity is usu-
ally more severe during gait than at rest. Patients present a 
swaying, scissor-like, shuffling gait. Age at onset is widely 
variable, from early childhood to late adulthood. An early 
sign of spastic paraplegia is the wearing down of the soles 
of the shoes at the toes and on the inner sides, because of 
the typical spasticity of adductor muscles and tiptoe gait.
Historically, cases are distinguished as pure or compli-
cated on clinical grounds (Harding 1983), even if recent 
knowledge of these diseases has demonstrated that this 
is not always correlated with their genetic bases and can 
vary between patients in the same family. Pure forms are 
characterized by pyramidal signs, associated with mus-
cle weakness and bladder dysfunction, but patients may 
also have decreased vibration sense at ankles or pes cavus. 
Patients rarely need a wheelchair but may use canes during 
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the corticospinal tracts as the main pathological character-
istic. They are considered one of the most heterogeneous 
neurological disorders. All modes of inheritance have been 
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with other diseases of the nervous system. The systematic 
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ing, is unmasking unusual phenotypes or inheritance modes 
associated with mutations in HSP genes and related genes 
involved in various neurological diseases. A new nosology 
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new data to replace the current classification. Collectively, 
functions of the known genes implicate the disturbance of 
intracellular membrane dynamics and trafficking as the 
consequence of alterations of cytoskeletal dynamics, lipid 
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the disease course, and they have usually, except in some 
clinico-genetic entities, a normal lifespan. In complicated 
forms, additional neurological signs are observed, such as 
cerebellar signs, neuropathy, mental/cognitive impairment, 
epilepsy, extrapyramidal and retinal signs, as well as extra-
neurological signs such as gastroesophageal reflux, cataract 
and abnormal skin pigmentation. In complex forms, the 
functional handicap and lifespan will depend on the full 
clinical picture.
At present, therapeutic options are very limited. For all 
patients except those with inborn errors of metabolism, 
rehabilitation therapies with an interdisciplinary approach 
to maintain autonomy as much as possible, physiotherapy 
and training are the best treatment options. Regular physi-
cal therapy is important to maintain muscle strength and 
to preserve range of motion and, based on passive tendon 
stretching, gait and equilibrium rehabilitation. According to 
the functional repercussion of spasticity, medications such 
as oral baclofen, intramuscular botulinum toxin or intrathe-
cal baclofen can be of some benefit to patients. Orthopedic 
options such as special shoes for pes cavus or achilles ten-
dotomy for equinovarus are also proposed to allow a longer 
autonomous gait. Sphincter disturbances should be investi-
gated by specialists and with a view to possible treatment 
with anticholinergics, antimuscarinic agents or botulinum 
toxin injections into the bladder (Fink 2013; Ginsberg et al. 
2013). Additional symptoms of complex forms can also be 
treated, such as parkinsonism with levodopa (Anheim et al. 
2009).
Exclusion diagnosis
There are various acquired and genetic causes that should 
be ruled out in patients with the symptom of spastic para-
plegia without a family history (Table 1). Cerebral and spi-
nal magnetic resonance imaging (MRI) investigations are 
important to rule out common neurological conditions and 
structural anomalies (e.g., spinal cord compression). For 
example, a frontal interhemispheric tumor may manifest as 
progressive spastic paraplegia with sphincter disturbances 
before other signs such as cognitive deterioration, headache 
or visual troubles appear. Disease progression, age at onset, 
additional symptoms and results from other supplementary 
investigations such as cerebrospinal fluid (CSF) analyses, 
blood biochemistry and serology, electroneuromyography 
and ophthalmological examination can give important clues 
to the diagnosis (Table 1). All these investigations will first 
exclude acquired causes of spastic paraplegia but will sub-
sequently help with the diagnostic workflow to find the 
correct genetic diagnosis. Some apparently sporadic cases 
are in fact masked familial diseases. The absence of a fam-
ily history in neurogenetic disorders is frequent in clinical 
practice and several explanations for apparent isolation are 
reduced penetrance, age-dependent penetrance, variable 
expressivity, de novo mutation, early death of the transmit-
ting parent or underdiagnosis in pure dominant forms with 
mild symptoms, autosomal recessive inheritance in small 
kindreds or, more rarely, X-linked inheritance in affected 
men. Among other inherited neurogenetic conditions that 
must be ruled out are leukodystrophies, in the absence of 
inflammation but in the presence of MRI abnormalities. 
Biochemical analyses in serum and/or CSF can suggest 
neurometabolic diseases. Finally, dopa-responsive dysto-
nias (DRD) are a group of autosomal dominant or recessive 
diseases, which may present with spasticity and can mimic 
HSP. The dystonic toe is well known and can be misdiag-
nosed as extensor plantar reflex (Furukawa et al. 2001). 
Diurnal fluctuations and high and sustained sensibility to 
levodopa are characteristic of DRD.
The exploration of rare genetic disorders is an impor-
tant issue since some diseases associated with spasticity 
are treatable. In particular, spastic paraparesis can be one of 
the multiple presentations of inborn errors of metabolism in 
children and adults and in some cases the symptom spastic 
paraparesis remains the only symptom for years; therefore, 
these metabolic causes should be included in the general 
diagnostic approach to sporadic spastic paraparesis due to 
treatment options (e.g., diet for argininemia, biotin in bioti-
nidase deficiency) (Tanyel and Mancano 1997; Sedel et al. 
2007) (www.treatable-id.org).
Genetic aspects of HSP
Genetic analysis of HSP genes can be performed when, 
according to the clinical symptoms and signs, other impor-
tant causes have been excluded. HSP genes are denoted 
Spastic Paraplegia Gene followed by a number according to 
their order of discovery (SPGn). Up to now, the clinical phe-
notype and age at onset were critical to prioritize molecular 
testing because of the heterogeneity of these diseases at the 
clinical and genetic levels (Supplementary Fig. S1). More 
than 25 novel causative genes have been reported in 2013–
2014 due to next-generation sequencing methods, making 
this genetic workflow time-consuming (Martin et al. 2013; 
Oates et al. 2013; Boukhris et al. 2013; Landouré et al. 
2013; Novarino et al. 2014; Dor et al. 2014; Esteves et al. 
2014; Crow et al. 2014), even if there are some genes that 
are still more frequent than others and may be analyzed first, 
such as SPAST (SPG4) and KIAA1840 (SPG11) (see below). 
All classical modes of transmission can be found and there 
are at least 67 genes that, when mutated, can account for 
these diseases (Table 2) to which can be added additional 
genes for which spasticity can be present as part of the clini-
cal presentation (Supplementary Table 1).
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Autosomal dominant (AD) forms of HSP are mainly 
pure forms with ages at onset that can range from 
infancy to late adulthood. Mutations in SPAST (SPG4), 
ATL1 (SPG3), KIF5A (SPG10) and REEP1 (SPG31) are 
described as being responsible for around 50 % of all 
cases (Fig. 1) (Finsterer et al. 2012). SPAST point muta-
tions and exonic rearrangements have been implicated in 
10–40 % of the HSP patients (Hazan et al. 1999; Meijer 
et al. 2002; Beetz et al. 2006; Loureiro et al. 2013) and in 
up to 12 % of sporadic forms (Depienne et al. 2006).
The autosomal recessive (AR) forms appear to be 
particularly prevalent where consanguinity is common 
such as in the Middle East or Mediterranean countries 
(Coutinho et al. 1999; Boukhris et al. 2009; Ruano et al. 
2014), and lesser frequent in central Europe, Japan (Tak-
iyama 2014) and USA (with the exception of communi-
ties such as the Amish). They are also more complex in 
clinical terms, associated with greater genetic heteroge-
neity (Table 2) with an onset of symptoms that is gen-
erally early. Only two forms are associated with pure 
HSP, but this likely results from the assignment of few 
families each: SPG71 and SPG72. In complex forms, the 
associated signs may be subtle but important indicators 
of the mutated gene, such as cerebellar atrophy or cer-
ebellar ataxia with optic atrophy in SPG7, developmen-
tal delay and short stature in SPG20 (Troyer syndrome), 
dysarthria, distal amyotrophy, premature aging and cog-
nitive decline in SPG21 (Mast syndrome), peripheral 
neuropathy and abnormal skin and hair pigmentation in 
SPG23 (Lison syndrome) (Table 2). Mental retardation 
or intellectual deterioration, thin corpus callosum (TCC) 
and axonal neuropathy are highly suggestive of SPG11 
(Stevanin et al. 2008a). Finally, spastic ataxia with dys-
arthria, nystagmus and retinal striations is suggestive 
of autosomal recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS). Mutations in the CYP7B1 (SPG5), 
SPG7, KIAA1840 (SPG11) and ZFYVE26 (SPG15) 
genes are among the most frequently found but their 
relative frequencies vary according to the geographical 
origin (Stevanin et al. 2008a; Paisan-Ruiz et al. 2008; 
Erichsen et al. 2009; Goizet et al. 2009a; Schüle et al. 
2009b; Arnoldi et al. 2012; Klebe et al. 2012a; Pfeffer 
et al. 2014) (Fig. 1). Point mutations or rearrangements 
in KIAA1840 (SPG11) have been shown to account 
for approximately 20 % of AR-HSP (Stevanin et al. 
2008a).
X-linked forms are rare and include two clinical entities 
well recognized by pediatricians (Table 2): SPG1, caused 
by mutations in the neural cell adhesion molecule L1CAM 
gene, and SPG2, which results from mutations in the gene 
encoding the proteolipid protein (PLP1), a myelin compo-
nent. SPG2 can also account for late-onset cases in women 
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Phenotype–genotype correlations in HSP
Many studies have failed in the past to determine reliable 
phenotype–genotype correlations. However, the systematic 
analysis of a large set of genes, including exome sequenc-
ing, is regularly unmasking unusual phenotypes and inher-
itance modes associated with mutations in HSP genes and 
the nature of the mutation in some of them can now be cor-
related to a specific phenotype.
Instances where similar mutations are associated with a 
wide spectrum of HSP phenotypes; extension of the 
clinical picture previously observed
There are good examples of variable phenotypes among HSP 
subtypes, as SPG4 in which age at onset can vary from early 
childhood to asymptomatic status at old ages. As more fami-
lies are reported with a mutation in a specific gene, the full 
spectrum of each genetic entity extends and there are now 
fewer than ten HSP loci/genes associated exclusively with 
pure forms of the disease, most of them accounting for sin-
gle or only a few families so far (Table 2; Supplementary 
Table 1). This was the case, for example, with SPG10, which 
was initially thought to be a pure form but now also accounts 
for 10 % of the complex AD families (Goizet et al. 2009b). 
In SPG7, the occurrence of cerebellar ataxia and/or atrophy 
(Klebe et al. 2012a) or progressive external ophthalmoplegia 
(Wedding et al. 2014; Pfeffer et al. 2014) suggests that the 
analysis of this gene should be extended to other phenotypes. 
Patients with isolated optic neuropathy should also be tested 
for mutations on SPG7 (Klebe et al. 2012a).
Instances where the nature of the mutations of a specific 
HSP gene can determine the inheritance model and/or 
associated phenotype
One of the recent advances in HSP genetics is the identi-
fication of various modes of inheritance of the mutations 
in single HSP genes. This is what occurs for REEP2 muta-
tions that have recently been implicated in three families 
with recessive or dominant transmission of a pure HSP, 
namely SPG72 (Novarino et al. 2014; Esteves et al. 2014). 
In one Portuguese family with AR inheritance, two muta-
tions segregated in trans including a splice site mutation 
leading to a loss of function of the corresponding allele 
and a missense mutation responsible for reduced binding 
capacities to membranes of the protein formed from the 
second allele. In a French autosomal dominant family, the 
disease segregated with a heterozygous missense muta-
tion that had a dominant negative effect on the capacity of 
the wild-type protein to bind membranes. In both cases, 
AD and AR mutations led to a complete loss of membrane 
binding capacities of the REEP2 protein with consequences 
for the tubular structure of the endoplasmic reticulum (ER) 
(Esteves et al. 2014). Recently, position p.Arg415 of Atlas-
tin-1 (SPG3A) was shown to be a hotspot for missense 
mutations, first associated with incomplete penetrance 
with an AD inheritance pattern (D’Amico et al. 2004), and 
then with AR transmission (Varga et al. 2013) (Khan et al. 
2014). Similarly, an unusual recessive or dominant inher-
itance has been suggested in SPAST (SPG4, Lindsey et al. 
2000) and SPG7 (McDermott et al. 2001; Sánchez-Ferrero 
et al. 2013), respectively.
The nature of the mutation and/or its localization in the 
protein can sometimes impact both the inheritance model 
and the phenotype at the same time, so that the nature of the 
mutation can predict the phenotype. This was observed with 
KIF1A (SPG30), in which missense homozygous mutations 
located in the kinesin motor domain account for a relatively 
pure HSP (Erlich et al. 2011; Klebe et al. 2012b), whereas 
heterozygous mutations located in the ATP binding site of 
KIF1A were found in patients with severe mental retarda-
tion with axial hypotonia, peripheral spasticity and mild 
atrophy of cerebellum and or corpus callosum, a pheno-
type reminiscent of SPG11 (Hamdan et al. 2011; Chang 
et al. 2014). Homozygous KIF1A frameshift mutations lead 
Fig. 1  Relative frequencies of 
the main autosomal dominant 
(a) and recessive (b) mutations 
in the SPATAX (http://spatax.
wordpress.com/) cohort (Goizet 
et al. 2009a, b, 2011; Steva-
nin et al. 2008a; Tesson et al. 
(2012); unpublished data)
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to hereditary sensory neuropathy type IIC (Rivière et al. 
2011). Similarly, heterozygous mutations in HSPD1 lead 
to SPG13 (Hansen et al. 2002), but homozygous missense 
mutations of the same gene are implicated in hypomyelinat-
ing leukodystrophy type 4 (Magen et al. 2008). Mutations 
in TFG are responsible for SPG57, an AR-HSP associated 
with optic atrophy and neuropathy (Beetz et al. 2013) but 
can also be responsible for AD motor and sensory neuropa-
thy (Ishiura et al. 2012). Interestingly, the TFG mutations 
affect different domains of the protein: the coil–coil domain 
in the HSP family, the P/Q rich domain in the family with 
neuropathy, suggesting different pathological mechanisms. 
In addition, one patient with neuropathy had ubiquitin- and 
TDP43-positive cytoplasmic neuronal inclusions reminis-
cent of amyotrophic lateral sclerosis (ALS) (Supplementary 
Table 2), suggesting a toxic gain of function effect result-
ing in a dominant inheritance pattern. In contrast, biallelic 
mutations affect the capacity of TFG to self-assemble and 
then probably lead to a loss of function (Beetz et al. 2013). 
This is also the case with REEP1, in which frameshift muta-
tions or missense mutations that abolish ER targeting and 
affect the capacity of the protein to bind ATL1 (Falk et al. 
2002; Beetz et al. 2012) lead to HSP (Züchner et al. 2006; 
Beetz et al. 2008; Hewamadduma et al. 2009; Goizet et al. 
2011), whereas in-frame deletions do not impact the capac-
ity of the protein to bind ATL1 and lead to hereditary motor 
neuropathy type V (Beetz et al. 2012).
Instances where the mutations of a specific HSP gene lead 
to overlapping diseases
During the past few years, it has appeared that HSP and 
other neurological conditions are at opposite ends of a 
continuum of overlapping diseases. The clinical overlap 
of HSP with peripheral neuropathies, cerebellar ataxias or 
mental disabilities is not new since mutated HSP patients 
can have a clinical presentation associating symptoms spe-
cific to these groups of disorders. ARSACS is a good illus-
tration of this clinical overlap between ataxias and spastic 
paraplegias (Bouhlal et al. 2011). It is sometimes difficult 
to decide which symptom is most prominent in the clinical 
presentation and this may also depend on the physician’s 
expertise. The overlap between HSP and ataxias was again 
recently highlighted by mutations in GBA2 (SPG46), which 
have been found in patients with spastic ataxia associated 
with cataract, having ataxia (Hammer et al. 2013; Votsi 
et al. 2014) or spasticity (Martin et al. 2013; Citterio et al. 
2014) as the prominent clinical feature. Point mutations 
and exonic deletions in KIF1C have both been reported in 
HSP (Novarino et al. 2014) and spastic ataxia (Dor et al. 
2014), illustrating the fact that both diseases are part of 
the same clinical spectrum. PNPLA6 mutations are found 
in patients with a wide range of phenotypes: Gordon Hol-
mes spinocerebellar syndrome (ataxia with brisk reflexes 
and hypogonadism), Boucher-Neuhäuser syndrome (ataxia 
with chorioretinal dystrophy and hypogonadism), isolated 
cerebellar ataxia and isolated spastic paraplegia (SPG39) 
(Rainier et al. 2008; Synofzik et al. 2014).
Regarding motor neuron diseases and polyneuropathies 
(Fig. 2), HSP genes have been found mutated in patients with 
(i) peripheral nerve affections such as Charcot–Marie–Tooth 
(CMT) neuropathies, (ii) first and secondary motor neuron 
degeneration, such as ALS, and (iii) lower motor neuron dis-
orders such as spinal muscular atrophy (SMA). For exam-
ple, KIAA1840 (SPG11) mutations may mimic ALS5 when 
muscle wasting is marked in absence of other complicated 
Fig. 2  Clinico-genetic entities 
associated with hereditary spas-
tic paraplegia (HSP) according 
to the motor neuron phenotypic 
presentation. When mutated, 
HSP genes can be associated 
with various phenotypes that 
overlap with upper and lower 
motor neuron diseases
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signs, or complex HSP in presence of cerebellar and cog-
nitive signs (Stevanin et al. 2007b, 2008a; Orlacchio et al. 
2010; Daoud et al. 2012; Romagnolo et al. 2014). Similarly, 
mutations in TFG can also be associated with HSP (SPG57) 
and ALS-like presentations (Ishiura et al. 2012; Beetz et al. 
2013). BIDC2 mutations are mainly responsible for SMA 
phenotypes but can cause HSP as well (Neveling et al. 2013; 
Oates et al. 2013). ERLIN2 mutations are responsible for 
SPG18 (Yıldırım et al. 2011; Alazami et al. 2011; Wakil 
et al. 2013) but also account for juvenile primary lateral 
sclerosis, another neurodegenerative disorder of the upper 
motor neuron overlapping HSP phenotype (Al-Saif et al. 
2012). Finally, missense mutations in KIF5A affecting the 
kinesin motor domain, or in MARS (SPG70) encoding the 
methionyl-tRNA synthase essential for protein biosynthesis 
(Deniziak and Barciszewski 2001), are responsible for pure 
(Reid et al. 2000) or complex forms of HSP with neuropa-
thy or amyotrophy (Tessa et al. 2008; Goizet et al. 2009b; 
Musumeci et al. 2011; Crimella et al. 2012; Collongues et al. 
2013; Novarino et al. 2014; Liu et al. 2014) but also CMT 
(Crimella et al. 2012; Gonzalez et al. 2013; Liu et al. 2014). 
In MARS, the mutations identified in CMT-like disease and 
in HSP patients are located in different domains.
Other examples are the FA2H and C9ORF12 genes, 
which can be found mutated in patients with neuronal 
brain iron accumulation (NBIA) or spastic paraplegia 
(Edvardson et al. 2008; Schneider and Bhatia 2010; Dick 
et al. 2010; Kruer et al. 2010; Hartig et al. 2011; Landouré 
et al. 2013). There are also two genes in which mutations 
are associated with complex HSP but also account for pon-
tocerebellar hypoplasia: AMPD2 (SPG63) and EXOSC3 
(Wan et al. 2012; Zanni et al. 2013; Novarino et al. 2014). 
GJC2 accounts for complex HSP associated with dysar-
thria, cerebellar ataxia and mental impairment (Orthmann-
Murphy et al. 2009) and hypomyelinating leukodystrophy 
Pelizaeus–Merzbacher-like disease (Uhlenberg et al. 2004). 
Similarly, PGAP1 and C12ORF65 have been reported 
mutated in encephalomyopathies (Antonicka et al. 2010; 
Murakami et al. 2014), but they are also mutated in patients 
with complex HSP (Shimazaki et al. 2012; Tucci et al. 
2013; Spiegel et al. 2014; Novarino et al. 2014).
Instances where mutations can either account for HSP or 
multisystemic disorders
Several genes mutated in HSP can also be responsible for 
multisystemic disorders in which spasticity can be part of 
the phenotype or even absent. Some of these genes cause 
developmental disorders such as those involving muta-
tions in genes coding for adaptor protein complex 4 (AP4) 
(SPG47, 50, 51 and 52) (Moreno-De-Luca et al. 2011; 
Abou Jamra et al. 2011). KIAA0196 is mutated in pure 
AD-HSP (SPG8) patients (Valdmanis et al. 2007), but also 
in complex cases in which the spasticity decreased upon 
levodopa treatment (Bettencourt et al. 2013), and recently 
a homozygous splice site mutation leading to exon 27 
skipping was involved in Ritscher–Schinzel syndrome, a 
developmental syndrome with craniofacial abnormalities, 
congenital heart defects and cerebellar brain malformations 
(Elliott et al. 2013).
Biallelic mutations in IBA57, encoding a Fe/S mito-
chondrial protein assembly factor, can be responsible for 
a slowly progressive childhood-onset HSP (Lossos et al. 
2015), up to multiple mitochondrial dysfunction syndrome 
3 (MMDS3; OMIM #615330), a severe lethal encephalopa-
thy with multiple malformations, myopathy and hypergly-
cinemia (Ajit Bolar et al. 2013). Mutations in LYST were 
first described in Chediak–Higashi syndrome, a disease 
characterized by decreased pigmentation, photophobia, 
nystagmus and abnormal susceptibility to infection (Bar-
bosa et al. 1997). Recently, one mutation was reported in a 
family with late-onset complex HSP with cerebellar ataxia, 
peripheral neuropathy and large peroxidase-positive gran-
ules in granulocytes (Shimazaki et al. 2014).
Finally, biallelic mutations in BSCL2 are responsible for 
congenital generalized lipodystrophy type 2, characterized 
by severe lipoatrophy, insulin resistance, hypertriglyceri-
demia and mental retardation (Magré et al. 2001). In con-
trast, heterozygous missense mutations in its N-glycosyla-
tion motif (p.Asn88Ser and p.Ser90Leu) result in a toxic 
gain of function by ER-stress-mediated cell death responsi-
ble for motor neuron diseases, including SPG17 and hered-
itary motor neuropathy type V (Windpassinger et al. 2004; 
Ito and Suzuki 2009).
Modifying factors
One striking observation is the large interfamilial but also 
intrafamilial phenotypic variability regarding age at onset 
and disease severity between patients, particularly in auto-
somal dominant HSP subtypes. Some SPG4 patients within 
the same family and carrying the same mutation may 
indeed remain asymptomatic throughout their life whereas 
others have an early onset and are severely affected and 
may present with additional features such as cognitive 
impairment and peripheral neuropathy. One major issue 
is therefore the identification of environmental or genetic 
modifiers in HSP. This has been especially studied in 
SPAST-positive patients; three modifier variants have been 
suggested so far: the rare p.Ser44Leu and p.Pro45Gln poly-
morphisms in SPAST and the p.Gly563Ala polymorphism 
located in HSPD1 (HSP60/SPG13) (Svenson et al. 2004; 
Bross et al. 2008). Large population studies are still lacking 
to validate these findings.
Phenotypic variability is well known in mitochondrial 
disorders. The mitochondrial MT-TI mutation segregating 
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in a HSP family is associated with a disease severity that 
is correlated to the level of heteroplasmy: from pure HSP 
in the proband showing 55 % heteroplasmy levels in mus-
cles, to a multisystemic disorder with cardiomyopathy in 
the brother with heteroplasmy levels of 90 % (Corona et al. 
2002).
Sex-dependent penetrance or severity has been sug-
gested for SPAST mutations on the basis of a significant 
excess of affected males (Starling et al. 2002; Proukakis 
et al. 2011) and/or an earlier age at onset (Mitne-Neto et al. 
2007) This was also suggested for ATL1 mutations (Varga 
et al. 2013; Luo et al. 2014).
In other cases, a variant may be pathogenic when inher-
ited as a recessive trait but may become a susceptibility 
factor for other neurological conditions at the heterozy-
gous state. Recent observations in the gene encoding par-
aplegin are striking. SPG7 patients usually have pure or 
complex forms of HSP, mainly associated with cerebellar 
signs and optic atrophy. Interestingly, heterozygous carri-
ers of SPG7 truncating mutations can develop a late-onset 
cerebellar syndrome/atrophy without spasticity, suggesting 
a predisposition for late-onset neurodegenerative disorders 
of heterozygous SPG7 carriers, mimicking an autosomal 
dominant inheritance when children are carrying two caus-
ative mutations. Moreover, patients with the heterozygous 
p.Asp411Ala mutation were reported with optic atrophy 
without ataxia or spasticity in a large autosomal dominant 
kindred. SPG7 has, therefore, to be considered in patients 
with late-onset cerebellar signs or optic atrophy, even in the 
absence of spasticity (Klebe et al. 2012a).
Genetic diagnosis of HSP
A genetic diagnosis workflow to be used in routine diagno-
sis is proposed in Supplementary Fig. 1 when new technol-
ogies are still not available. In sporadic and AD cases, ATL1 
and SPAST genes should be tested first depending on age at 
onset. Of note, up to 12 % of sporadic cases are mutated in 
the SPAST gene (Depienne et al. 2006; Beetz et al. 2006) 
while up to 40 % are mutated among autosomal dominant 
forms. Since 50 % of the mutations in SPG4 are larger 
deletions, duplications or complex genomic rearrangements 
(Beetz et al. 2006; Depienne et al. 2007), a dedicated tech-
nique (array-CGH, MLPA) has to be used in parallel. In AR 
cases, the genes to be tested are based on the associated 
phenotype. Indeed, the relative frequency of SPG11 var-
ies according to phenotype (Stevanin et al. 2008a). SPG11 
accounts for <1 % of patients with a pure phenotype, 4.5 % 
of cases with spastic paraplegia and cognitive impairment 
without thinning of the corpus callosum (TCC), but up to 
59 % of persons with early-onset progressive spasticity 
with mild intellectual disability and/or cognitive decline 
associated with TCC. The other HSP genes are analyzed 
depending on the inheritance mode, the clinical presenta-
tion and the results of additional examinations.
However, the number of causative genes is growing very 
rapidly thanks to the improvement of sequencing tech-
niques, and the classical testing of one gene after the other 
is progressively being replaced by diagnostic kits allowing 
multiple genes to be tested in parallel. Access to all SPG 
variants with such techniques may open opportunities to 
analyze their modifier effects in addition to the causative 
mutation in the near future. This may also represent a chal-
lenge for the interpretation of their effects since multiple 
variants with potential effects will likely be identified in 
more than one candidate gene. The development of common 
databases and of bioinformatics but also biological pipelines 
for analysis of the pathogenic effects will be required and 
will sometimes complicate the diagnosis workflow.
When a mutation is identified, genetic counseling and 
prenatal and presymptomatic testing are possible options.
Physiopathology of HSP
Known HSP genes encode proteins involved mainly in ER 
morphogenesis, microtubule dynamics and transport, mito-
chondrial quality control, lipid metabolism and endosomal/
lysosomal functions (Table 3), and collectively suggest that 
HSP might be caused by impaired cellular trafficking (Ste-
vanin et al. 2008b; Blackstone 2012).
Clear evidence of impaired trafficking comes from the 
involvement of KIF5A (SPG10), KIF1A (SPG30) and 
KIF1C (SAX2/SPAX2/SPG58), which are motor pro-
teins (kinesins) involved in organelle/vesicle trafficking. 
In KIF5A, heterozygous missense mutations in the motor 
domain are associated with a reduced velocity along micro-
tubules in gliding assays (Ebbing et al. 2008). There is also 
other evidence of trafficking disturbances in HSP. Neurons 
from knockout (KO) mice for Spast present with a marked 
impairment of microtubule dynamics along axons, accom-
panied by axonal swelling and cargo stalling (Tarrade 
et al. 2006; Kasher et al. 2009; Fassier et al. 2013). Spastin 
(SPAST/SPG4) is a microtubule-severing protein, which 
links cytoskeletal dynamics to membrane remodeling in 
several cellular processes. Abnormal axonal swellings have 
been also reported in Plp1, Fa2h and Kif5a KO mice and/or 
fly models (Edgar et al. 2004; Potter et al. 2011; Füger et al. 
2012; Karle et al. 2012). Axon swellings with accumulation 
of membranous material in axons have also been observed 
in Spg7 KO mice (Ferreirinha et al. 2004) and in nerve 
biopsies of SPG11 patients (Hehr et al. 2007). Finally, 
axonal trafficking of vesicles was shown to be impaired in 
neurons derived from induced pluripotent stem cells (IPSC) 
of SPG11 patients (Pérez-Brangulí et al. 2014).
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Chromosome Protein Protein function
SPG1 L1CAM
(308840)
Xq28 L1 cell adhesion molecule Axonal guidance
SPG2 PLP1
(300401)
Xq22.2 Proteolipid protein 1 Myelin component










2p22.3 Spastin Microtubule dynamics, BMP signaling
SPG5/SPG5A CYP7B1
(603711)
8q12.3 Cytochrome P450, family 7, subfamily B, 
polypeptide 1




15q11.2 NIPA1/non-imprinted in Prader Willi/Angel-
man syndrome 1
Mg2+ transporter
Inhibitor of BMP pathway
SPG7 SPG7
(602783)
16q24.3 Paraplegin Component of the m-AAA protease
SPG8 KIAA0196
(610657)
8q24.13 Strumpellin Actin remodeling
SPG10 KIF5A
(602821)
12q13.3 Kinesin heavy chain isoform 5A Motor protein, axonal transport
SPG11 KIAA1840
(610844)
15q21.1 Spatacsin Lysosome shaping
SPG12 RTN2
(603183)
19q13.32 Reticulon 2 ER shaping
SPG13 HSPD1
(118190)
2q33.1 Heat shock 60 kDa protein 1/chaperonin Mitochondrial chaperone
SPG15 ZFYVE26
(612012)
14q24.1 Spastizin Lysosome shaping, cytokinesis, autophagy
SPG17 BSCL2
(606158)
11q12.3 Seipin ER protein, scaffolding protein for lipid 
metabolism and lipid droplet formation
SPG18 ERLIN2
(611605)
8p11.23 SPFH2 ER-associated degradation pathway (ERAD)
SPG20 KIAA0610
(607111)
13q12.3 Spartin Cytokinesis, BMP signaling, Lipid droplet 




15q22.31 Maspardin Associated predominantly with markers for 




Xq13.2 Solute carrier family 16 (monocarboxylic 









14q22.1 DDHD domain containing 1 Phospholipase A1, lipid metabolism
SPG30 KIF1A
(601255)
2q37.3 Kinesin family member 1A Motor protein, axonal anterograde transport
SPG31 REEP1
(609139)
2p11.2 Receptor expression-enhancing protein 1 ER-shaping, mitochondrial functions?
SPG33 ZFYVE27
(610244)










19p13.2 Patatin-like phospholipase domain contain-
ing 6/neuropathy target esterase (NTE)
Lipid metabolism
Membrane curvature
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Chromosome Protein Protein function
SPG42 SLC33A1
(603690)





19p13.11-q12 Chromosome 19 open reading frame 12 –
SPG44 GJC2
(608803)
1q42.13 Gap junction protein, gamma 2, 47 kDa Oligodendrocyte connexin
SPG46 GBA2
(609471)
9p13.3 Glucocerebrosidase 2 Lipid metabolism
SPG47 AP4B1
(607245)

































8p22 Vacuolar protein sorting 37 homolog A Member of the ESCRT-I complex
SPG54 DDHD2
(615003)
8p11.23 DDHD domain containing 2 Phospholipase, lipid metabolism
SPG55 C12orf65
(613541)




4q25 See SPG49a and TECPR2a
SPG57 TFG
(602498)








15q21.2 Ubiquitin specific peptidase 8 Deubiquitination enzyme
SPG60 WDR48
(612167)
3p22.2 WD repeat domain 48 Deubiquitination regulation
SPG61 ARL6IP1
(603158)





10q24.31 ER lipid raft associated 1 ER-associated degradation
SPG63 AMPD2
(102771)




10q24.1 Ectonucleosidase triphosphate diphosphory-
lase 1














2q33.1 GPI inositol deacylase GPI-AP sorting by ERES
SPG68 FLRT1
(604806)
11q13.1 Fibronectin leucine rich transmembrane 
protein 1
FGF pathway
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The best known example of mitochondrial dysfunction 
in HSP is related to the SPG7 subtype. The corresponding 
gene is the first to have been identified in HSPs, in 1998 
(Casari et al. 1998) and encodes paraplegin. Paraplegin is a 
conserved subunit of the ATP-dependent m-AAA protease 
of the inner membrane of the mitochondria involved in the 
quality control of multiple proteins of the respiratory path-
way. SPG7 is associated with multiple mitochondrial DNA 
deletions, suggesting that functions of other mitochondrial 
proteins involved in either mitochondrial DNA replication 






Chromosome Protein Protein function
SPG69 RAB3GAP2
(609275)
1q31 RAB3 GTPase activating protein subunit 2 ER morphology
SPG70 MARS
(156560)
12q13.3 Methionyl-tRNA synthetase Cytosolic methionyl-tRNA synthetase
SPG71 ZFR
(615635)
5p13.3 Zinc finger RNA binding protein –
SPG72 REEP2
(609347)
5q31.2 Receptor expression-enhancing protein 2 ER shaping
No SPG ADAR1
(146920)
1q21.3 Adenosine deaminase RNA-specific RNA metabolism
No SPG BICD2
(609797)




5p15.2 Chaperonin containing TCP1, subunit 5 Cytosolic chaperonin
No SPG EXOSC3
(606489)




5p15.1 FAM134B Golgi protein
No SPG IFIH1
(606951)





1q42.3 Lysosomal trafficking regulator protein Lysosome fusion/fission regulation
No SPG MAG
(159460)
19q13.1 Myelin-associated glycoprotein Myelination
No SPG MT-ATP6
(516060)
Mitochondrial Complex V, ATP synthase, subunit ATPase 6 Respiratory chain complex V subunit
No SPG MT-CO3
(516050)
Mitochondrial Cytochrome c oxydase III/Complex IV Respiratory chain complex IV subunit
No SPG MT-TI
(590045)
Mitochondrial Isoleucine transfer RNA (Mitochondrial) Mitochondria
No SPG RNASEH2B
(610326)









14q32.31 Tectonin beta-propeller repeat containing 2 Autophagy pathway
No SPG VCP
(601023)




1q42 Iron–sulfur cluster assembly homolog Part of the iron–sulfur cluster (ISC) assembly 
machinery in mitochondria
(m)AAA (mitochondrial) ATPase associated with diverse cellular activities, BMP bone morphogenetic pathway, ER endoplasmic reticulum, 
ERES ER exit sites, ESCRT endosomal sorting complexes required for transport, FGF fibroblast growth factor, GPI-AP glycosylphosphatidylin-
ositol-anchor protein, IMP inositol monophosphate
a
 According to the HUGO nomenclature, SPG49 has been associated with CYP2U1 mutations and SPG56 has not been associated to a specific 
gene. According to the OMIM numbering, SPG49 has been associated to TECPR2 mutations and SPG56 to CYP2U1 mutations
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itself or pathways of mitochondrial quality control are 
altered (Wedding et al. 2014). As a consequence, SPG7 
patients present with reduced mitochondrial respiration 
rates and increased sensitivity to oxidative stress (Atorino 
et al. 2003). Spg7 KO mice show axonal swellings with 
accumulation of membranous material and mitochondria in 
distal axons (Ferreirinha et al. 2004) reminiscent of what 
is observed in Spg4/Spast KO mice and therefore making 
the link between mitochondrial alterations and intracellular 
trafficking defects. Recently, reduced levels and activities 
of mitochondrial 4Fe-4S mitochondrial proteins have been 
observed in a family with a combination of spastic paraple-
gia, optic atrophy, and peripheral neuropathy (SPOAN) due 
to IBA57 mutations (Lossos et al. 2015). Finally, impaired 
mitochondrial motility was shown in neurons derived from 
iPSC of SPG3A patients (Zhu et al. 2014), again linking 
trafficking and mitochondrial functions; mitochondrial 
distribution is dependent on microtubule cytoskeleton and 
tubular ER functions.
The number of HSP proteins involved in the functions 
of the ER is growing. Six genes related to these functions 
are mutated in HSP (Goyal and Blackstone 2013). Atlas-
tin-1 is a GTPase able to promote ER tubule homotypic 
fusion by forming trans-oligomeric complexes between 
two adjacent ER tubules (Orso et al. 2009). Rismanchi 
et al. (2008) showed ER morphology effects of the mutant 
atlastin-1 while ER-Golgi trafficking was largely unaf-
fected. Another subgroup of proteins acts in ER shaping: 
ARL6IP1 (SPG61), reticulon 2 (SPG12), REEP1 (SPG31), 
REEP2 (SPG72) and RAB3GAP2 (Montenegro et al. 2012; 
Novarino et al. 2014; Esteves et al. 2014). Of note, spas-
tin, atlastin-1 and REEP1 have been found to interact with 
each other and to act on microtubule interactions with the 
tubules of the ER (Park et al. 2010).
The secretory pathway is also altered. Spatacsin 
(SPG11) and spastizin (SPG15) account for proteins 
involved in the formation of lysosomes (Chang et al. 
2014) and interact with components of the AP5 complex 
involved in membrane sorting of late endosomes (Hirst 
et al. 2013). Another adaptor protein complex, AP4, is also 
involved in neurodevelopmental diseases overlapping with 
HSP: SPG50, SPG51, SPG47 and SPG52 (Moreno-De-
Luca et al. 2011; Abou Jamra et al. 2011). Accumulation 
of giant lysosomes and autophagosomes was observed in 
patient’s cells and in a Drosophila KO for Lyst, suggesting 
that LYST plays a role in homotypic fusion of these orga-
nelles (Rahman et al. 2012). BICD2 is an adaptor protein 
necessary for retrograde transport of vesicles from ER to 
Golgi (Heffernan and Simpson 2014). Finally, the NIPA1 
protein (SPG6) is a neuron-specific transmembrane protein 
principally localized in the early endosomal compartment 
and on the plasma membrane, and its ortholog in Drosoph-
ila (Spict) was shown to interact with bone morphogenetic 
protein (BMP) receptors and promote their internalization 
from the membrane (Wang et al. 2007). BMP signaling is 
necessary for normal microtubule cytoskeleton assembly, 
and NIPA1 mutants are less efficient in the lysosomal deg-
radation of BMP receptors, therefore, interfering with dis-
tal axonal functions (Tsang et al. 2009).
There are some subtypes of HSP that affect multiple 
brain regions and are associated with an early onset of the 
symptoms, which include psychomotor delay. These disor-
ders include the SPGs affecting the AP4 complex as well 
as SPG1 and SPG2. In SPG3A and SPG11, the early onset 
of the disease may also suggest an abnormal development 
but information is lacking to confirm this point. A good 
example of abnormal development is SPG1. L1CAM func-
tion is necessary for correct formation of the corticospinal 
tract. Indeed, mice lacking L1cam mimic the human phe-
notype and present with defects in axonal guidance in the 
corticospinal tracts and reduced decussation (Cohen et al. 
1998). Of note, abnormal development leading to psycho-
motor delay has also been suspected in HSP due to muta-
tions in PGAP1 (SPG67) (Novarino et al. 2014).
Some genes expressed almost exclusively in glial cells 
have been identified in HSP, such as SLC16A2 coding for 
MCT8, a thyroid hormone transporter expressed by astro-
cytes during embryonic development in mammals. Several 
other proteins involved in HSP are expressed predomi-
nantly in non-neuronal cells, such as MAG and PLP1, two 
components of myelin, and FA2H, an enzyme involved 
in the hydroxylation of sphingolipids, galactolipids and 
other fatty acids (Hiroko 2010). Mice lacking Fa2h show 
a degeneration of myelin sheaths at 18 months (Zöller 
et al. 2008). PLP1/DM20 is expressed in oligodendrocytes 
and oligodendrocyte progenitor cells (OPC). Despite nor-
mal myelination, mice lacking Plp1 have physically frag-
ile myelin and a decrease of its cholesterol content (Wer-
ner et al. 2013). It can be suggested that PLP1/DM20 may 
stabilize and maintain the myelin sheath. Moreover, these 
mice have an alteration of fast retrograde and anterograde 
transport (Edgar et al. 2004).
Lipid metabolism is an emerging pathway in HSP, but 
its importance is growing daily and has opened an entirely 
novel perspective on the pathogenesis of this group of dis-
eases. There is increasing evidence that lipids have critical 
roles as signaling mediators and effectors, and that lipid 
composition of neuronal membranes affects crucial pro-
cesses such as exocytosis and ion channel functions, and 
contributes to the formation of membrane domains. As an 
example, the loss of the B4GALNT1, an enzyme of the 
catabolism of complex gangliosides, changes the choles-
terol and phospholipid content of membranes (Ohmi et al. 
2011). B4galnt1 KO mice show an age-dependent neu-
rodegenerative phenotype, central and peripheral axonal 
degeneration, reduced myelin volume and loss of axo-glial 
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junctions. This phenotype was rescued by B4GALNT1 
expression in neurons but not by B4GALNT1 glial expres-
sion, indicating that neuronal rather that glial gangliosides 
are important for integrity of the CNS (Yao et al. 2014). 
On the other hand, SPG5 encodes an enzyme of the bilic 
acid and neurosteroid formation (CYP7B1). SPG5 physi-
opathology may result from an accumulation of toxic sub-
strates and the absence of neurosteroids (Leoni and Cac-
cia 2011; Theofilopoulos et al. 2014). In Gba2 KO mice, 
the accumulation of glucocerebrosides has been shown in 
brain, liver and testis (Gonzalez-Carmona et al. 2012), but 
only infertility has been explored in these mice and whether 
this accumulation is toxic in the brain is not proved. Lipid 
storage may also be affected in some of these diseases 
since Atlastin-1, REEP1, Spartin and Seipin modulate lipid 
droplet structures (Renvoisé et al. 2012; Klemm et al. 2013; 
Falk et al. 2014).
Altogether, the functional knowledge gained from the 
known functions of the HSP genes and from the analysis 
of various animal models of these diseases suggest that the 
pathology results from disturbance of intracellular mem-
brane trafficking and may account for the ‘dying-back’ 
mechanism observed in neuropathological human cases 
(Supplementary Table 2) (Deluca et al. 2004). The rela-
tionship between most of the genes involved in HSP has 
recently been pinpointed by the publication of an HSP 
interactome that may be useful to incriminate further 
causative genes in the future (Novarino et al. 2014). Very 
recently, nucleotide metabolism and autophagy were also 
novel functions reported as possibly altered in HSP (Oz-
Levi et al. 2012; Novarino et al. 2014).
Conclusions
The increasing number of genes and the extension of the 
clinical picture associated with each genetic entity are 
building a new nosology that may modify the way molec-
ular diagnosis and treatment of these diseases is done. 
Although it is often impossible to identify the mutated 
HSP gene in an individual patient on the basis of clinical 
criteria, the relative frequencies and clinical characteristics 
still help to elaborate an effective diagnostic strategy after 
careful exclusion of other causes. The strategy is simple 
in certain cases because of the high relative frequencies 
of two major genes: SPG4, which represents up to 40 % 
of pure AD forms, and SPG11, which accounts for up to 
59 % of cases with a TCC transmitted in an AR manner. 
However, numerous studies have shown that the classic 
subdivision of HSP into pure and complex forms, still in 
use in clinical practice, is imperfect. In addition, the clini-
cal and genetic overlap of various neurodegenerative dis-
eases suggests that HSP is (or indeed the HSPs are) in a 
continuum with other neurological diseases and that the 
phenotype of a given patient will depend on multiple fac-
tors, including the mutated gene, the nature of the muta-
tion and its location in the protein, the zygosity of the 
mutation, modifier variants and the environment. When 
considering all factors, it becomes clear that the dogma 
linking one gene to one phenotype has to be replaced by 
one patient—one disease, which will fit with personalized 
medicine in the future. On the other hand, there is indica-
tion for a possible unification of genetic forms from the 
cell biological and, thus, potentially therapeutic point of 
view. In particular, the functions of several recently identi-
fied HSP proteins suggest that they may participate in the 
same molecular pathway of lipid metabolism, which may 
lead to common therapies. Interestingly, disturbances in 
lipid metabolism also offered the unprecedented opportu-
nity to identify biomarkers for HSP, as in SPG5 (25 and 
27 hydroxy-cholesterol) (Schüle et al. 2010) and SPG26 
(testosterone or GM2/GM3 levels) (Boukhris et al. 2013; 
Harlalka et al. 2013) (Table 2; Supplementary Table 1), 
prerequisite for therapeutic trials. Finally, elucidation of 
the underlying pathogenic mechanisms will also help to 
develop more effective therapeutic agents. Preclinical tri-
als in Spast KO flies and mice (ex vivo) and SPG4 human 
embryonic stem cells indicated that microtubule-binding 
agents might have therapeutic value (Fassier et al. 2013; 
Denton et al. 2014). Similarly, these drugs proved to be 
efficient in rescuing axon growth defects in SPG3A iPSC 
(Zhu et al. 2014) which open therapeutic avenues for HSP 
subtypes related to abnormal trafficking.
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